嘉和生物-B(06998.HK)香港發售股份超購約1246.52倍 預計10月7日掛牌上市
格隆匯 10 月 6日丨嘉和生物-B(06998.HK)發佈公告,公司全球發售約1.2億股股份,其中香港發售股份5994.1萬股,國際發售股份5994萬股,另有15%超額配股權;發售價釐定為每股發售股份24.00港元,每手買賣單位500股;預期股份將於2020年10月7日於聯交所主板掛牌上市。
香港公開發售項下初步發售的香港發售股份獲大幅超額認購。合共接獲491,364份有效申請,認購合共約149.57億股股份,相當於香港公開發售項下初步可供認購香港發售股份總數約1,247.52倍。國際發售項下初步提呈發售的發售股份已獲超額認購,相當於國際發售項下初步可供認購發售股份總數約33.0倍。
基於發售價每股發售股份24.00港元,根據基石投資協議,基石投資者已認購合共5994萬股發售股份,合計佔緊隨全球發售完成後公司已發行股本總額的約12.46%及全球發售項下發售股份數目的約50%,兩種情況均假設超額配股權未獲行使。
按發售價每股發售股份24.00港元計算,公司將收到的全球發售所得款項淨額估計約為26.937億港元。公司擬將所得款項淨額的42%用於為核心產品的研發活動提供資金,包括正在進行及計劃進行的臨牀試驗、適應症擴展及註冊備案籌備以及商業化;所得款項淨額的23%用於為其他主要產品的研發活動提供資金,包括正在進行及計劃進行的臨牀試驗、適應症擴展及註冊備案籌備;15%用於撥付管線中其他候選藥物正在進行及計劃進行的臨牀試驗、適應症擴展及註冊備案籌備;10%用於為藥物管線擴展提供資金;及10%作一般企業用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.